RxDoctor Payments Data

Franklin Harris, MD

Psychiatry · Baton Rouge, LANPI 1700800653

Payments from drug & device makers

$771in general payments, 2019–2025

Across 30 payments — averaging $25.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$186
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$119
  • E.r. Squibb & Sons, L.L.C.$100
  • AbbVie$78
  • Neurocrine Biosciences, Inc.$66
  • Sunovion Pharmaceuticals Inc.$66
  • plus $155 from 6 others

What the payments were for

  • Food & beverage$61179%
  • Education$16021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$771 in reported general payments places this provider in the 55th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$53,102
Medicare patients
145
Services billed
611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate44$134,897
TrintellixVortioxetine Hydrobromide25$12,028
SaphrisAsenapine Maleate13$7,600
Olanzapine OdtOlanzapine76$6,446
Quetiapine Fumarate316$4,394
Varenicline Tartrate14$3,058
Ziprasidone Hcl35$2,911
Chlorpromazine Hcl12$2,596
Paliperidone ErPaliperidone23$1,716
Clonazepam123$1,334
Bupropion XlBupropion Hcl72$1,308
Mirtazapine73$1,155
Trazodone Hcl147$1,112
Hydroxyzine Pamoate73$1,090
Doxepin Hcl33$1,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$28$134,89744 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$23$12,02825 claims
AbbVieSaphris$78$7,60013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →